Dr. Shravan Subramanyam, MD of BPL Medical Technologies
The reduction of GST on life-saving drugs, diagnostic kits, and medical equipment from 12% to 5% is a landmark reform. For patients, this translates into lower treatment costs and better access to advanced medical care. For us, it allows greater price competitiveness, helping us pass on the benefit to customers while strengthening our reach across hospitals, clinics, and homecare segments. We see this as a big enabler for growth, as it supports our mission of delivering affordable, world-class, ‘Made in India’ medical solutions while empowering us to scale up innovation and expand into newer markets.
